The case of complement inhibitors.
Adv Biol Regul
; 81: 100822, 2021 08.
Article
in English
| MEDLINE | ID: covidwho-1364204
ABSTRACT
Severe COVID-19 is characterized by lung and multiorgan inflammation and coagulation in the presence of overactivation of the complement system. Complement is a double edged-sward in SARS-Cov-2 infection. On one hand, it can control the viral infection in milder cases, on the other hand in cases with severe and prolonged infection massive complement activation occurs, which can intensify lung and systemic inflammation and promote a procoagulant and prothrombotic state. Several uncontrolled studies and controlled clinical trials with different complement inhibitors have been performed and others are ongoing. Results are promising in some but negative in others. Further studies are required to elucidate the benefit to risk profile of complement inhibitors in COVID-19 patients at different stages of the disease and to clarify the best targets in the complement cascade.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Complement System Proteins
/
Complement Activation
/
Complement Inactivating Agents
/
SARS-CoV-2
/
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Adv Biol Regul
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS